Clinical Trial Update: Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GEMOX with or without erlotinib in unresectable/metastatic biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Tarceva (erlotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Unresectable, Metastatic Biliary Tract Carcinoma | Phase 3 | Status: COMPLETED